TY - JOUR
T1 - Raltitrexed plus oxaliplatin in the treatment of metastatic colorectal cancer
AU - Cortinovis, Diego
AU - Bajetta, Emilio
AU - Di Bartolomeo, Maria
AU - Dognini, Giuseppina
AU - Beretta, Elena
AU - Ferrario, Erminia
AU - Ricotta, Riccardo
AU - Buzzoni, Roberto
PY - 2004/3
Y1 - 2004/3
N2 - Aims and background: As raltitrexed and oxaliplatin (L-OHP) are both effective in the treatment of colorectal cancer but have different mechanisms of action, we studied the antitumoral activity and safety of their combined use in patients with advanced colorectal cancer. Methods: A 15-min intravenous infusion of raltitrexed (2.5 mg/m2) and a 180-min infusion of oxaliplatin (100 mg/m2) were administered on day 1 every three weeks for a maximum of six cycles. Results: The study involved 51 patients (27 males and 24 females) with a median age of 65 years (range, 43-78); 28 were aged ≥65 years. The primary tumor site was the colon in 35 patients and the rectum in 16. Thirty-four patients had received prior chemotherapy: 20 as adjuvant treatment and 14 as pretreatment. The most frequent metastatic sites were liver (18 cases), lung (10 cases), liver + lung (8 cases) and lymph nodes (3 cases). Twenty-four patients completed the entire treatment plan. The most common toxicities were transaminitis (16 patients, grade 3-4), diarrhea (six patients, grade 3), nausea/vomiting (one patient, grade 4), and asthenia (one patient, grade 3). The treatment was stopped in one patient because of prolonged grade 4 transaminitis. The adverse event profile was similar in the patients aged >65 years and
AB - Aims and background: As raltitrexed and oxaliplatin (L-OHP) are both effective in the treatment of colorectal cancer but have different mechanisms of action, we studied the antitumoral activity and safety of their combined use in patients with advanced colorectal cancer. Methods: A 15-min intravenous infusion of raltitrexed (2.5 mg/m2) and a 180-min infusion of oxaliplatin (100 mg/m2) were administered on day 1 every three weeks for a maximum of six cycles. Results: The study involved 51 patients (27 males and 24 females) with a median age of 65 years (range, 43-78); 28 were aged ≥65 years. The primary tumor site was the colon in 35 patients and the rectum in 16. Thirty-four patients had received prior chemotherapy: 20 as adjuvant treatment and 14 as pretreatment. The most frequent metastatic sites were liver (18 cases), lung (10 cases), liver + lung (8 cases) and lymph nodes (3 cases). Twenty-four patients completed the entire treatment plan. The most common toxicities were transaminitis (16 patients, grade 3-4), diarrhea (six patients, grade 3), nausea/vomiting (one patient, grade 4), and asthenia (one patient, grade 3). The treatment was stopped in one patient because of prolonged grade 4 transaminitis. The adverse event profile was similar in the patients aged >65 years and
KW - Colorectal cancer
KW - Elderly patients
KW - Oxaliplatin
KW - Raltitrexed
UR - http://www.scopus.com/inward/record.url?scp=2942624024&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=2942624024&partnerID=8YFLogxK
M3 - Article
C2 - 15237580
AN - SCOPUS:2942624024
VL - 90
SP - 186
EP - 191
JO - Tumori
JF - Tumori
SN - 0300-8916
IS - 2
ER -